Congenital muscular dystrophy, Fukuyama type: A Patient Guide

Congenital muscular dystrophy, Fukuyama type (FCMD) is a rare genetic condition that fundamentally changes how the body builds and maintains its most vital structures. Unlike many other forms of muscular dystrophy that primarily affect the skeletal muscles, classic FCMD is characterized by a unique combination of muscle weakness, significant brain development changes, and eye involvement ^[1]. This occurs because of a mutation in the FKTN gene, which normally helps “sugar-coat” a protein that acts like a molecular glue, anchoring cells in the muscles, brain, and eyes to their surroundings. When this glue is missing or defective, these cells become fragile and cannot organize themselves properly during early development ^[2][3]. It is important to note that while classic FCMD is severe, FKTN mutations can cause a broader spectrum of FKTN-related dystroglycanopathies, ranging from severe congenital forms to milder muscle-predominant conditions.

While FCMD is seen in families of various backgrounds, it is most frequently identified in the Japanese population due to a specific “founder mutation” that has been passed down through generations ^[4]. From the earliest days of life, parents may notice that their infant feels “floppy” or has difficulty reaching milestones like holding their head up or sitting without support ^[1]. Because the brain’s surface does not form its typical folds—a pattern known as cobblestone lissencephaly—children often experience moderate-to-severe intellectual disabilities and are at a higher risk for developing seizures as they grow ^[1][5].

Living with FCMD involves managing a disease that is both multisystem and progressive. Over time, the focus of care often shifts from physical therapy and motor milestones to supporting the internal systems that the body relies on for survival ^[6]. The muscles that control breathing and the heart muscle itself can weaken, requiring specialized baseline respiratory assessments and cardiac monitoring rather than waiting for age-based complications ^[7][8]. Because these changes can happen quietly, staying ahead of them through an individualized surveillance plan is the cornerstone of modern management ^[9].

Despite these challenges, the standard of care has evolved significantly toward a proactive, multidisciplinary approach. By surrounding a child with a team of experts—including neurologists, pulmonologists, rehabilitation specialists, and early palliative care for symptom support—families can address symptoms early and prioritize their child’s comfort and engagement with the world ^[9]. Ongoing research into genetic “patches” and other emerging therapies continues to offer hope for better ways to treat the underlying cause of this condition, ensuring that every child has the support they need to navigate their unique journey ^[10].